This story is available exclusively to Insider subscribers. Become an Insider and start reading now.
A top healthcare VC predicted microbiome drugs would rebound in 2021 as part of Business Insider s year-end roundup of healthcare predictions.
Though the biotech industry s infatuation with the promise of the bacteria in our gut dates back years, research failures and the 2019 uBiome scandal previously chilled investors interests.
More established microbiome companies have continued the search to prove the microbiome can bear fruit for patients and investors alike.
Seres Therapeutics, currently valued at $2.4 billion, is the space s clear frontrunner, having announced success last August in a late-stage study for one of its microbiome drug candidates.